4/19
03:09 pm
brns
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Report
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.